Always a few "if and buts" in these, isn't there. But leaving...

Always a few "if and buts" in these, isn't there. But leaving aside the uncertainty of timing I reckon you are right DDD. The overhang being cleared is a really good thing. The possibility of (i) oncology asset sale, (ii) a forthcoming payment from the partner, and/or (iii) a clinical trial outcome will surely provide a fair bit of upward pressure on the SP. After all, a few of us have been waiting for any one of these things to occur. A couple of them in short succession might almost prove the analysts' targets correct. GLTA